Single Agent Samba? Doublet Dance? Mambo Combo? Mastering the Rhythm of Treatment Selection and Sequencing in Renal Cell Carcinoma – Tweetorial #4




Provided by Integrity Continuing Education, Inc.


This activity is supported by educational grants from Eisai, Inc. and Merck Sharp & Dohme Corp.


This activity will help clinicians to develop a treatment plan when considering the use of new and emerging systemic treatments for their patients with advanced renal cell carcinoma (aRCC).


The standards of care for aRCC have been evolving at an ever-accelerating pace over the last 20 years. Improvements in the understanding of the immunogenic nature and pathogenic drivers of this disease uncovered synergistic mechanisms between immunotherapies and antiangiogenic treatments that were previously used in single-agent treatment strategies.

This led to the new “gold standard” of first-line treatment for aRCC, which is to combine immuno-oncology (IO) using the immune checkpoint inhibitors (ICIs) and antiangiogenic tyrosine kinase inhibitors (TKIs) that block vascular endothelial growth factor and its receptors. This combination strategy has extended progression-free survival and overall survival beyond what could previously be hoped for with TKI or ICI monotherapy.

Determining which patient should receive which combination has become a complex question with no clear consensus. As additional combination strategies advance in clinical trials, the question gets ever-more complicated.

This program will increase your ability to assess the efficacy and safety data from new and emerging combinations and aid your treatment decision-making process for these patients.


Robert Motzer, MD
Kidney Cancer Section Head
Genitourinary Oncology
Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York


Sumanta K. Pal, MD, FASCO
Professor, Department of Medical Oncology
Co-Director, Kidney Cancer Program
City of Hope Comprehensive Cancer Center
Duarte, California


Brian I. Rini, MD, FASCO
Ingram Professor of Medicine
Vanderbilt University Medical Center
Chief of Clinical Trials
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee


Release date: January 20, 2022
Expiration date: January 20, 2023
Estimated time to complete activity: 15 minutes



This educational activity has been designed to meet the needs of oncologists, pathologists, histologists, nephrologists, urologists and fellows, and other professionals involved in the management of patients with RCC particularly in the community setting.


Upon completion of this educational activity, participants should be able to:

  • FORMULATE a plan to consider new and emerging systemic treatments as they become available for appropriately selected patients with aRCC

There are no fees for participating and receiving CME credit for this activity. During the period of January 20, 2022 to January 20, 2023, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.




Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this other activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Robert Motzer, MD
Consulting Fees: Aveo, EMD Serono, Eisai, Exelixis, Genentech/Roche, Merck, Novartis, Pfizer
Research: Aveo, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Pfizer, Merck, Novartis

Sumanta K. Pal, MD, FASCO has no real or apparent conflicts of interest to disclose.

Brian Rini, MD, FASCO
Consulting Fees: 3DMedicines, Alkermes, Aveo, Compugen, Corvus, Eisai, Shionogi, Synthorx
Research Funding (Institution): AstraZeneca, Dragonfly Therapeutics, Exelixis, Hoffman-LaRoche, Immunomedics, Incyte, Mirati Therapeutics, Seattle Genetics, Taris
Consulting Fees/Research Funding (Institution): Aravive, Arrowhead Pharmaceuticals, Bristol-Myers Squibb, Genentech-Roche, GlaxoSmithKline, Pfizer, Merck, Surface Oncology
Stock: PTC Therapeutics

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


Continue to Pretest